1,823 Shares in Krystal Biotech, Inc. (NASDAQ:KRYS) Purchased by Blueshift Asset Management LLC

Blueshift Asset Management LLC acquired a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 1,823 shares of the company’s stock, valued at approximately $332,000.

Several other hedge funds have also recently bought and sold shares of KRYS. Segall Bryant & Hamill LLC boosted its position in shares of Krystal Biotech by 352.4% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company’s stock worth $28,605,000 after acquiring an additional 122,407 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of Krystal Biotech by 1,972.0% in the 2nd quarter. Principal Financial Group Inc. now owns 123,469 shares of the company’s stock valued at $22,674,000 after purchasing an additional 117,510 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Krystal Biotech by 115.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company’s stock valued at $35,583,000 after purchasing an additional 103,928 shares during the last quarter. Public Sector Pension Investment Board acquired a new position in shares of Krystal Biotech during the 2nd quarter worth $10,037,000. Finally, Rhumbline Advisers lifted its position in shares of Krystal Biotech by 123.3% during the 2nd quarter. Rhumbline Advisers now owns 71,685 shares of the company’s stock worth $13,164,000 after buying an additional 39,586 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Stock Performance

Krystal Biotech stock opened at $196.91 on Friday. The stock has a market capitalization of $5.66 billion, a price-to-earnings ratio of 111.25 and a beta of 0.82. Krystal Biotech, Inc. has a 52-week low of $99.00 and a 52-week high of $219.34. The stock’s 50 day moving average price is $180.23 and its two-hundred day moving average price is $183.28.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business had revenue of $83.84 million during the quarter, compared to analysts’ expectations of $82.94 million. During the same period last year, the company posted ($0.67) earnings per share. The business’s quarterly revenue was up 879.9% on a year-over-year basis. On average, equities research analysts forecast that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the sale, the insider now owns 1,500,882 shares in the company, valued at $296,814,424.32. The trade was a 1.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 14.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have commented on KRYS shares. Citigroup boosted their target price on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Stifel Nicolaus raised their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Finally, Evercore ISI raised their price objective on Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a report on Monday, August 12th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Krystal Biotech has an average rating of “Buy” and a consensus price target of $202.29.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).